Get the Stockscreener App
6.18
1.12%
-0.07
Coya Therapeutics Inc stock is traded at $6.18, with a volume of 268.07K.
It is down -1.12% in the last 24 hours and up +1.48% over the past month.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
See More
Previous Close:
$6.25
Open:
$6.29
24h Volume:
268.07K
Relative Volume:
1.41
Market Cap:
$129.31M
Revenue:
-
Net Income/Loss:
$-14.88M
P/E Ratio:
-6.3061
EPS:
-0.98
Net Cash Flow:
$-10.29M
1W Performance:
+2.66%
1M Performance:
+1.48%
6M Performance:
+15.08%
1Y Performance:
+6.19%
1-Day Range:
$6.12
$6.44
1-Week Range:
$5.95
$6.44
52-Week Range:
$4.65
$8.29
Coya Therapeutics Inc Stock (COYA) Company Profile
Name
Coya Therapeutics Inc
Sector
Industry
Phone
650.739.3939
Address
12645 MEMORIAL DR., SUITE F1 #305, HOUSTON
Compare COYA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COYA
Coya Therapeutics Inc
|
6.18 | 130.78M | 0 | -14.88M | -10.29M | -0.98 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Coya Therapeutics Inc Stock (COYA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-09-25 | Initiated | Lake Street | Buy |
| Dec-04-24 | Initiated | D. Boral Capital | Buy |
Coya Therapeutics Inc Stock (COYA) Latest News
Coya Therapeutics, Inc. (NASDAQ:COYA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Responsive Playbooks and the COYA Inflection - news.stocktradersdaily.com
Buy Rating for Coya: Phase 2 Trial Initiation and Financial Milestones Boost Prospects - TipRanks
Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS - BioSpace
Coya Therapeutics, Inc.: Promising Advancements in ALS and FTD Treatment with COYA-302 - TipRanks
D. Boral Capital Maintains Coya Therapeutics (COYA) Buy Recommendation - Nasdaq
Coya Therapeutics Announces Patients Have Been Dosed in the Alstars Trial of Coya 302 for the Treatment of Als - marketscreener.com
Coya Therapeutics' (COYA) "Buy" Rating Reaffirmed at D. Boral Capital - MarketBeat
Eisai Still Confident in Anti-Tau Asset as J&J Becomes Latest Victim in Spiraling Space - BioSpace
Coya Therapeutics (COYA) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Understanding the Setup: (COYA) and Scalable Risk - news.stocktradersdaily.com
Investor Presentation (12/01/2025 00: 00 - marketscreener.com
Highs Report: Is Coya Therapeutics Inc. stock a top momentum play2025 Growth vs Value & Advanced Swing Trade Entry Plans - BỘ NỘI VỤ
HC Wainwright Lifts Earnings Estimates for Coya Therapeutics - MarketBeat
Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences - BioSpace
Form 424B5Prospectus [Rule 424(b)(5)] - ADVFN
H.C. Wainwright Maintains Coya Therapeutics(COYA.US) With Buy Rating, Maintains Target Price $18 - 富途牛牛
H.C. Wainwright reaffirms Buy rating on Coya Therapeutics stock at $18 target - Investing.com Canada
Coya Therapeutics: Strong Financial Position and Upcoming Catalysts Support Buy Rating - TipRanks
What drives Coya Therapeutics Inc stock pricePortfolio Risk Assessment & Outstanding Growth Portfolio - earlytimes.in
D. Boral Capital Initiates Coverage of Coya Therapeutics (COYA) with Buy Recommendation - MSN
Is Coya Therapeutics Inc. stock a buy before product launchesJuly 2025 Outlook & Short-Term Trading Alerts - newser.com
Is Coya Therapeutics Inc. stock cheap at current valuationJuly 2025 Catalysts & Daily Risk Controlled Trade Plans - newser.com
The Technical Signals Behind (COYA) That Institutions Follow - news.stocktradersdaily.com
Can Coya Therapeutics Inc. stock weather global recessionBull Run & Risk Controlled Stock Pick Alerts - newser.com
How Coya Therapeutics Inc. stock performs in interest rate cycles2025 Breakouts & Breakdowns & AI Powered Market Entry Strategies - newser.com
Why Coya Therapeutics Inc. stock could benefit from AI revolutionTrade Risk Report & Fast Exit/Entry Strategy Plans - newser.com
Price momentum metrics for Coya Therapeutics Inc. explained2025 Biggest Moves & Daily Risk Controlled Trade Plans - newser.com
Coya Therapeutics, Inc. (NASDAQ:COYA) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Is Coya Therapeutics Inc. still worth holding after the dipMarket Trend Review & Growth Focused Stock Reports - newser.com
What to do if you’re stuck in Coya Therapeutics Inc.2025 Historical Comparison & Smart Investment Allocation Tips - newser.com
Is Coya Therapeutics Inc. meeting your algorithmic filter criteriaJuly 2025 Closing Moves & AI Powered Buy/Sell Recommendations - newser.com
Coya Therapeutics (NASDAQ: COYA) starts Phase 2 COYA 302 ALS study in 120 patients - Stock Titan
What analyst consensus says on Coya Therapeutics Inc. stockCPI Data & Weekly Breakout Watchlists - newser.com
Coya Therapeutics (NASDAQ:COYA) Receives "Buy" Rating from Chardan Capital - MarketBeat
How to interpret RSI for Coya Therapeutics Inc. stockIndex Update & Reliable Price Breakout Alerts - newser.com
Will Coya Therapeutics Inc. continue its uptrendTrade Volume Summary & Daily Stock Trend Watchlist - newser.com
Coya Therapeutics Inc Stock (COYA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):